Chronos CEO wins European CEO, Best CEO in the Drug Discovery Industry
Chronos CEO, Dr Huw Jones has been awarded best CEO in the European drug discovery industry by online and print magazine European CEO. Read the press release.
Dr Timothy Schulz-Utermoehl to join as VP Pre-Clinical Development
Dr Schulz-Utermoehl has over 17 years’ experience in the pharmaceutical industry, spanning early and late-stage discovery research and pre-clinical development. He and Dr Fraser Murray will be [...]
Dr Fraser Murray joins as VP Pre-Clinical Development
Dr Murray brings more than 20 years’ of drug discovery and early development experience across a range of therapeutic areas, including neurodegeneration, psychiatry, inflammation and [...]
Dr Chris Towler appointed Non-Executive Director
Chris is a highly experienced investment and pharmaceutical professional with decades of experience in each sector, most recently as director of OSEM (Oxford Spin Out Equity Management).
Professor Peter Jenner joins as CSO
A leader in pre-clinical models of neurodegeneration, Peter has also been CSO of a successful public biotech company. He is also Emeritus Professor of Pharmacology at King’s College London.
Experienced research leader Dr Kevin Thompson joins as Director, Chronoscreen™
Dr Kevin Thompson, an experienced biotech executive in both screening and neuroscience, joins as Director, Chronoscreen™. Kevin has over 20 years’ experience of drug screening and [...]
